Cargando…

Real-World Clinical Outcomes of Biosimilar Trastuzumab (CT-P6) in HER2-Positive Early-Stage and Metastatic Breast Cancer

BACKGROUND: The trastuzumab biosimilar CT-P6 has demonstrated equivalent efficacy and comparable safety to reference trastuzumab (RTZ) in clinical trials of human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (EBC). Here, we present the first real-world comparison of CT-P6 v...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bae, Soong June, Kim, Jee Hung, Ahn, Sung Gwe, Jeung, Hei-Cheul, Sohn, Joohyuk, Kim, Gun Min, Kim, Min Hwan, Kim, Seung Il, Park, Seho, Park, Hyung Seok, Kim, Ji Ye, Jeong, Joon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8213064/ https://www.ncbi.nlm.nih.gov/pubmed/34150658 http://dx.doi.org/10.3389/fonc.2021.689587

Ejemplares similares

Anaemia and pathologic complete response rate according to carboplatin dose in HER2+ breast cancer treated with neoadjuvant TCHP
por: Ji, Jung Hwan, et al.
Publicado: (2022)

Axillary response according to neoadjuvant single or dual human epidermal growth factor receptor 2 (HER2) blockade in clinically node‐positive, HER2‐positive breast cancer
por: Cha, Chihwan, et al.
Publicado: (2021)

YAP1 Expression in HR+HER2− Breast Cancer: 21-Gene Recurrence Score Analysis and Public Dataset Validation
por: Park, Inho, et al.
Publicado: (2023)

Overexpression of Class III Beta Tubulin and Amplified HER2 Gene Predict Good Response to Paclitaxel and Trastuzumab Therapy
por: Jung, Minkyu, et al.
Publicado: (2012)

The Impact of Post-Mastectomy Radiotherapy on Survival Outcomes in Breast Cancer Patients Who Underwent Neoadjuvant Chemotherapy
por: Lee, Janghee, et al.
Publicado: (2021)

Prognostic value of neutrophil-to-lymphocyte ratio in human epidermal growth factor receptor 2-negative breast cancer patients who received neoadjuvant chemotherapy
por: Bae, Soong June, et al.
Publicado: (2020)

Validation of Clinical Treatment Score post-5 years (CTS5) risk stratification in premenopausal breast cancer patients and Ki-67 labelling index
por: Lee, Janghee, et al.
Publicado: (2020)

Author Correction: Validation of Clinical Treatment Score post-5 years (CTS5) risk stratification in premenopausal breast cancer patients and Ki-67 labelling index
por: Lee, Janghee, et al.
Publicado: (2021)

Next-generation sequencing of BRCA1/2 in breast cancer patients: potential effects on clinical decision-making using rapid, high-accuracy genetic results
por: Park, Hyung Seok, et al.
Publicado: (2017)

Efficacy and Safety of Trastuzumab Biosimilar (CT-P6) Compared With Reference Trastuzumab in Patients With HER2-positive Advanced Gastric Cancer: A Retrospective Analysis
por: Park, Joo-Hwan, et al.
Publicado: (2022)

Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18–14/KM10B)
por: Sim, Sung Hoon, et al.
Publicado: (2022)

Blood Test for Breast Cancer Screening through the Detection of Tumor-Associated Circulating Transcripts
por: Park, Sunyoung, et al.
Publicado: (2022)

A Phase II Study to Evaluate the Safety and Efficacy of Pegteograstim in Korean Breast Cancer Patients Receiving Dose-Dense Doxorubicin/Cyclophosphamide
por: Kim, Gun Min, et al.
Publicado: (2019)

Association between TP53 mutation and high 21-gene recurrence score in estrogen receptor-positive/HER2-negative breast cancer
por: Ji, Jung Hwan, et al.
Publicado: (2022)

Efficacy of Limited Dose Modifications for Palbociclib-Related Grade 3 Neutropenia in Hormone Receptor–Positive Metastatic Breast Cancer
por: Kim, Seul-Gi, et al.
Publicado: (2023)

Association between Skeletal Muscle Loss and the Response to Neoadjuvant Chemotherapy for Breast Cancer
por: Lee, Byung Min, et al.
Publicado: (2021)

Radiotherapy-Induced High Neutrophil-to-Lymphocyte Ratio is a Negative Prognostic Factor in Patients with Breast Cancer
por: Yoon, Chang Ik, et al.
Publicado: (2020)

On-treatment derived neutrophil-to-lymphocyte ratio and survival with palbociclib and endocrine treatment: analysis of a multicenter retrospective cohort and the PALOMA-2/3 study with immune correlates
por: Kim, Chang Gon, et al.
Publicado: (2023)

Incidence of Febrile Neutropenia in Korean Female Breast Cancer Patients Receiving Preoperative or Postoperative Doxorubicin/Cyclophosphamide Followed by Docetaxel Chemotherapy
por: Kim, Chang Gon, et al.
Publicado: (2016)

Assessment of the Molecular Mechanism of Action of SB3, a Trastuzumab Biosimilar
por: Paek, Kyungyeol, et al.
Publicado: (2019)

Detection of Circulating Tumor Cells in Breast Cancer Patients Using Cytokeratin-19 Real-Time RT-PCR
por: Park, Hyung Seok, et al.
Publicado: (2017)

Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer
por: Soo Park, Ji, et al.
Publicado: (2017)

Comparison of standardized uptake value of 18F-FDG-PET-CT with 21-gene recurrence score in estrogen receptor-positive, HER2-negative breast cancer
por: Ahn, Sung Gwe, et al.
Publicado: (2017)

Magnetic Resonance Imaging after Completion of Neoadjuvant Chemotherapy Can Accurately Discriminate between No Residual Carcinoma and Residual Ductal Carcinoma In Situ in Patients with Triple-Negative Breast Cancer
por: Park, Seho, et al.
Publicado: (2016)

Application of the 21-Gene Recurrence Score in Patients with Early HR-Positive/HER2-Negative Breast Cancer: Chemotherapy and Survival Rate According to Clinical Risk
por: Bae, Soong June, et al.
Publicado: (2021)

Drifts in ADCC-related quality attributes of Herceptin®: Impact on development of a trastuzumab biosimilar
por: Kim, Seokkyun, et al.
Publicado: (2017)

Anaplastic Lymphoma Kinase Gene Copy Number Gain in Inflammatory Breast Cancer (IBC): Prevalence, Clinicopathologic Features and Prognostic Implication
por: Kim, Min Hwan, et al.
Publicado: (2015)

CD44/CD24 and aldehyde dehydrogenase 1 in estrogen receptor-positive early breast cancer treated with tamoxifen: CD24 positivity is a poor prognosticator
por: Moon, Yong Wha, et al.
Publicado: (2017)

Systematic Review on the Use of Biosimilars of Trastuzumab in HER2+ Breast Cancer
por: Triantafyllidi, Eleni, et al.
Publicado: (2022)

Phase II study of a trastuzumab biosimilar in combination with paclitaxel for HER2-positive recurrent or metastatic urothelial carcinoma: KCSG GU18-18
por: Kim, M., et al.
Publicado: (2023)

Feasibility of Charcoal Tattooing of Cytology-Proven Metastatic Axillary Lymph Node at Diagnosis and Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy in Breast Cancer Patients
por: Park, Seho, et al.
Publicado: (2018)

A single arm phase Ib/II trial of first-line pembrolizumab, trastuzumab and chemotherapy for advanced HER2-positive gastric cancer
por: Lee, Choong-kun, et al.
Publicado: (2022)

Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2 + metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16)
por: Sim, Sung Hoon, et al.
Publicado: (2019)

Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+ breast cancer
por: Lammers, Philip E., et al.
Publicado: (2018)

Radiation dose-event relationship after intraoperative radiotherapy as a boost in patients with breast cancer
por: Cho, Yeona, et al.
Publicado: (2023)

Relationship of the standard uptake value of (18)F-FDG-PET-CT with tumor-infiltrating lymphocytes in breast tumors measuring ≥ 1 cm
por: Park, Soeun, et al.
Publicado: (2021)

Local Control of Brain Metastasis: Treatment Outcome of Focal Brain Treatments in Relation to Subtypes
por: Chong, Jae Uk, et al.
Publicado: (2015)

Metastasis Risk Assessment Using BAG2 Expression by Cancer-Associated Fibroblast and Tumor Cells in Patients with Breast Cancer
por: Yoon, Chang-Ik, et al.
Publicado: (2021)

Genomic landscape of extraordinary responses in metastatic breast cancer
por: Lim, Sun Min, et al.
Publicado: (2021)

A Case of Combined Hepatocellular-Cholangiocarcinoma with Favorable Response to Systemic Chemotherapy
por: Kim, Gun Min, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_4bd18a3r4gkfgudopu26qf1v8d